http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111979203-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111979203-B |
| titleOfInvention | Oncolytic vaccinia virus carrying CTTNBP2NL gene, construction method and use in the preparation of antitumor drugs |
| abstract | The invention relates to the technical field of biomedical engineering, and provides an oncolytic vaccinia virus carrying a CTTNBP2NL gene, a construction method and an application. The DNA sequence of the CTTNBP2NL gene is shown in SEQ ID NO: 1. The construction method of recombinant oncolytic vaccinia virus includes two steps: (A) insert the gene sequence of CTTNBP2NL into pCB plasmid through Xba I and Bgl II sites to obtain pCB-TTL plasmid; (B) pCB-TTL plasmid and vaccinia virus pass through After recombination in cells, after screening and identification, an oncolytic vaccinia virus carrying the CTTNBP2NL gene was obtained. The oncolytic vaccinia virus of the present invention not only has a significant inhibitory effect on various tumor cells, but also significantly improves the anti-tumor ability of the oncolytic vaccinia virus in tumor-bearing mice, and can inhibit tumor growth and prolong the survival time of tumor-bearing mice. All have been reflected, providing a new target for tumor virus therapy, with broad prospects for clinical application. |
| priorityDate | 2019-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 619.